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Hepatorenal syndrome (HRS) is one of the most ominous complications of portal hypertension in patients with decompen-
sated cirrhosis and ascites. It is associated with very high mortality on the wait list. Liver transplantation (LT) is the most suc-
cessful therapeutic option for patients with HRS. However, not all the LT candidates with HRS are able to receive a deceased 
donor allograft in a timely manner because it is a scarce resource and patients may need alternative best supportive treatment 
with systemic splanchnic vasoconstrictors and albumin as a bridge to transplant. The combination of terlipressin and albumin 
is efficacious in the reversal of HRS and is used worldwide. More recently, the multicenter, randomized, placebo-controlled 
double-blind study to confirm efficacy and safety of terlipressin in subjects with hepatorenal syndrome type 1 (the CONFIRM 
study) trial demonstrated the efficacy of terlipressin and albumin in the reversal of HRS in a North American cohort. The aim 
of this article is to review the role of terlipressin and albumin in LT candidates with HRS in the United States.
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Liver transplantation (LT) is a lifesaving procedure 
and the standard of care for patients with decompen-
sated liver disease. There were 8896 LTs performed in 
the United States in 2019(1) with 12,922 candidates 
awaiting LT as of February 17, 2020.(2) Policies based 
on the Model for End-Stage Liver Disease (MELD) 
score have revolutionized the allocation of livers from 
deceased donors in the United States.(3) Because serum 
creatinine (sCr) is one of the heavily weighted com-
ponents of MELD score,(4) the proportion for patients 
receiving LT with sCr ≥2  mg/dL or while on renal 
replacement therapy (RRT) has increased significantly 
in the MELD era(5,6) with a clear survival benefit for 
this cohort of very sick patients.(6) Moreover, the use of 
simultaneous liver and kidney transplants (SLKT) has 
also increased significantly in the MELD era.(7)
Acute kidney injury (AKI) is observed in 20% of 
hospitalized patients with decompensated cirrho-
sis and ascites.(8) It is associated with high morbidity 
and mortality.(8) AKI can be reversible or irreversible 
whether it is prerenal, renal, or postrenal AKI. In a 
cohort study, postrenal AKI was diagnosed in <1% 
of patients.(8) Hepatorenal syndrome (HRS) is a form 
of prerenal AKI that is nonresponsive to plasma vol-
ume expansion alone. As defined by the International 
Club of Ascites (ICA) in 1994, it is of 2 types, has 
limited treatment options, and carries a high mortality. 
Progressive worsening of HRS may lead to acute tubu-
lar necrosis in a minority of patients. More recently, 
HRS type 1 was renamed as HRS-AKI and HRS 
type 2 was renamed as HRS-non-AKI (NAKI) based 
on the Kidney Disease: Improving Global Outcomes 
(KDIGO) criteria (Table 1).(9,10)
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Terlipressin, a vasopressin analogue, together with 
albumin has been shown to improve renal function in 
patients with HRS type 1.(11-16) However, terlipres-
sin is not available in the United States. Recently, the 
multicenter, randomized, placebo-controlled double- 
blind study to confirm efficacy and safety of terlipres-
sin in subjects with hepatorenal syndrome type 1 (the 
CONFIRM study) trial showed the efficacy and safety 
of terlipressin and albumin in HRS type 1 reversal in 
North America.(17) The aim of this article is to review 
the role of terlipressin and albumin for patients with 
HRS type 1 listed for LT in the United States.
HRS: Pathophysiology and 
Definition
HRS, as originally defined with a sCr cutoff of 
2.5 mg/dL, occurs in 4% of hospitalized patients with 
decompensated cirrhosis and ascites.(8,18) The proba-
bility of developing HRS is 18% at 1 year and up to 
40% at 5 years.(19,20) The new definition of HRS does 
not include a final cutoff value of sCr, thus allowing the 
diagnosis to be made and pharmacological treatment 
to be initiated at early stages.(9,10)
The pathogenesis of HRS is multifactorial, triggered 
by splanchnic vasodilatation leading to central hypovole-
mia, circulatory dysfunction, and systemic inflammation 
(Fig. 1A). Splanchnic and systemic vasodilation cause 
a lowering of mean arterial pressure and central blood 
volume.(22,23) Such vasodilation and lowering of vascular 
resistance would normally be corrected by autoregula-
tory responses. However, both the baroreflex and car-
diovascular responses to angiotensin II, norepinephrine, 
and vasopressin are abnormal with portal hypertension, 
causing further blood pressure dysregulation. In response 
to the splanchnic vasodilation and central hypovolemia 
in advanced cirrhosis, the various systemic endogenous 
vasoconstrictor systems are activated.(24,25)
Cirrhotic cardiomyopathy, a phenomenon that affects 
both systolic and diastolic cardiac function, further exac-
erbates the circulatory dysfunction. Although cardiac 
output is often high in absolute terms because of the 
decreased systemic vascular resistance, the impaired func-
tion becomes apparent when either the resistance is nor-
malized or there is a physiological stress stimulus.(18,23,26,27)
Systemic inflammation as a result of pathogen- 
associated molecular patterns or damage-associated 
molecular patterns plays a key role in the development 
of organ failure and acute decompensation.(28,29) A 
 low-grade systemic proinflammatory state exists with 
elevated levels of cytokines, including interleukin 6 and 
tumor necrosis factor α, which may be associated with 
the translocation of enteric bacteria. Spontaneous bac-
terial peritonitis (SBP) is the most frequent infectious 
precipitant of HRS.(30) A total of 35% of patients with 
cirrhosis and ascites who develop SBP also develop AKI. 
Other bacterial infections can precipitate HRS, such as 
urinary tract or biliary tract infections.(8,14,18,23,27)
The interplay of various hemodynamic changes 
in patients with advanced cirrhosis and ascites as 
described here create the perfect storm when patients 
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tABle 1. new classification of hRS
Old Classification New Classification Criteria
HRS type 1 HRS-AKI • Absolute increase in sCr ≥0.3 mg/dL within 48 hours
• Urinary output ≤0.5 mL/kg body weight at ≥6 hours
• % increase in sCr ≥ 50% based on last outpatient sCr as baseline value
HRS type 2 HRS-NAKI HRS-AKD • eGFR <60 mL/minute/1.73 m2 for <3 months in the absence of other structural causes
• Percentage increase in sCr <50% using the last available value of outpatient sCr within  
3 months at baseline value
HRS-CKD • eGFR <60 mL/minute per 1.73 m2 for ≥3 months in the absence of other structural causes
NOTE: Adapted from Angeli et al.(9)
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are exposed to a “second hit” (hypovolemia, gastroin-
testinal bleed, dehydration, infection, etc.; Fig. 1B). 
The second hit typically leads to a further impairment 
of circulatory dysfunction and worsening renal perfu-
sion.(26) The kidneys autoregulate renal blood flow at 
blood pressures above 70 mm Hg. However, overacti-
vation of the sympathetic system increases the kidneys’ 
reliance on an adequate blood pressure to maintain 
renal perfusion. Constriction of the afferent and effer-
ent arterioles is caused by stimulation of α-adrener-
gic receptors and renin release both by reduced blood 
flow and β-adrenergic receptors.(25) Stimulation of the 
renin-angiotensin-aldosterone axis is further increased 
because of the inability of the cirrhotic liver to degrade 
renin.(25,31)
Historically, HRS was considered to be a single 
entity. In 1994, the ICA held a meeting at the American 
Association for the Study of Liver Diseases (AASLD) 
meeting in Chicago, and it was recognized that there were 
2 forms of HRS, type 1 and type 2 based on the sever-
ity and acuity of renal dysfunction.(32) This distinction 
was made to improve the greater understanding of the 
pathophysiology of HRS and to aid the design of clin-
ical trials with consistent efficacy endpoints. The more 
aggressive HRS type 1 (now called HRS-AKI), defined 
as a doubling of baseline sCr to a level >2.5  mg/dL 
FiG. 1. (A) The relationship of renal blood flow and preserved glomerular filtration rate in patients with decompensated cirrhosis and 
ascites. (B) The second hit leading to AKI in patients with decompensated cirrhosis and ascites. Adapted from Moreau and Labrec(21) 
(2003).
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in less than 2 weeks, has a 2-week median survival if left 
untreated. HRS type 2 (now called HRS-NAKI) has a 
more insidious onset in patients with refractory asci-
tes and moderate renal dysfunction (sCr ≥1.5 mg/dL), 
and it has a median survival of 4-6 months.(33) These 
cutoffs for baseline creatinine were arbitrary values that 
were determined partly to ensure homogeneity and to 
avoid inclusion of patients with prerenal AKI.
The ICA revised the definition of HRS in 2015(10) 
(Fig. 2A,B), and more recently in 2019(9) (Table 1) to 
incorporate it into a broad definition of AKI based on 
KDIGO criteria. These criteria define AKI in cirrhosis 
as an increase in sCr ≥0.3 mg/dL within 48 hours or a 
percentage increase in sCr ≥50% from baseline, which 
is known, or presumed, to have occurred within the past 
7 days.(9,10) The subclassifications of HRS type 1 and 
HRS type 2 with the limiting threshold of a sCr con-
centration of 2.5 mg/dL and the time limit of 2 weeks 
to diagnosis for HRS type 1 were removed because the 
evidence suggests that a higher pretreatment sCr is 
associated with a lower probability of response to terli-
pressin and albumin in patients with HRS type 1.(34,35)
It is important to distinguish between the phenotypes 
of AKI given the therapeutic and prognostic implica-
tions. This newer classification describes a new phe-
notypic classification of HRS in patients with cirrhosis 
FiG. 2. (A) IAC–AKI definitions for the diagnosis and management of AKI in patients with cirrhosis. (B) Diagnostic criteria of 
HRS-AKI in patients with cirrhosis. *Patients who fulfill these criteria may still have structural damage such as tubular damage. Urine 
biomarkers will become an important element in making a more accurate differential diagnosis between HRS and acute tubular necrosis. 
Adapted from Angeli et al.(9,10) (2015, 2017).
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based on pathophysiological characteristics (Table 1).(9) 
Non-HRS-AKI now includes other causes of AKI in 
patients with cirrhosis, such as bile salt nephropathy, 
prerenal hypovolemia caused by bleeding, excessive 
diuretic use, or any excessive fluid loss, acute tubular 
injury, and necrosis as well as AKI caused by intrinsic 
renal causes, such as acute interstitial nephritis. Despite 
the newer definition,(9,10) the majority of clinical trials 
examining the drug efficacy for HRS used the historical 
definitions for HRS type 1 and type 2. The downside of 
the use of arbitrary but relatively high cutoffs for sCr is 
that patients with early stage HRS were never entered 
into controlled clinical studies. As a result, patients being 
randomized into such clinical trials always had advanced 
AKI due to HRS using current criteria.(9,10)
Management of HRS-AKI: 
Terlipressin and Albumin
LT is the only definitive therapeutic option for HRS in 
listed patients with decompensated cirrhosis. Successful 
LT eliminates portal hypertension and advanced liver 
disease, which is the underlying clinical milieu within 
which HRS develops and usually results in renal recov-
ery after transplant.(36-38) However, only a minority of 
HRS patients are eligible for or able to undergo timely 
LT. In addition, because deceased donor organs are a 
scarce resource, patients may need to be optimized with 
various treatment strategies until an organ becomes 
available. Therapy with splanchnic vasoconstrictors and 
albumin is an effective option to improve renal dysfunc-
tion and may improve short-term wait-list survival.
Albumin is the preferred plasma expander for vol-
ume expansion in patients with decompensated cir-
rhosis.(39) It is used in conjunction with splanchnic 
vasoconstrictors for the treatment for HRS and in 
combination with antibiotics for the treatment of 
SBP for the prevention of HRS.(40) It is increasingly 
clear that the beneficial effects of albumin derive 
from a combination of the oncotic and nononcotic 
properties including its role as pleotropic scavenger, 
antioxidant, and immunomodulatory molecule.(41) 
Albumin infusion improves circulatory volume, 
increases plasma renin activity, and may reduce the 
severity of inflammation by binding to lipopolysac-
charides and other bacterial products.(42) Compared 
with albumin, alternative plasma expanders are less 
effective.(43) The recommended dose is 1 g of albumin 
per kilogram of body weight, with a maximum dose 
of 100 g/day. A meta-analysis of 19 studies suggested 
a significant dose-response benefit with albumin, 
with a 600-g cumulative dose of albumin (equivalent 
to 50 g/day given over a 12-day period) providing a 
90-day survival of 41% compared with 24.8% sur-
vival with a cumulative dose of 200-g albumin.(44)
Splanchnic vasoconstrictors like terlipressin exert 
their effect through vascular vasopressin V1 receptors 
in the splanchnic blood vessels, resulting in a reduc-
tion of portal pressure. The combination of terlipressin 
and albumin is efficacious in the reversal of HRS and 
is used worldwide. Previous studies have shown that 
baseline sCr and total bilirubin levels, grade of acute-
on-chronic liver failure (ACLF), and mean arterial 
pressure were independent predictors of the response 
to terlipressin in HRS.(15,34)
Because terlipressin is not approved by the US Food 
and Drug Administration, the therapeutic options for 
patients with HRS in the United States are limited to 
either a combination of octreotide and midodrine with 
albumin(12,16) in noncritically ill patients or noradren-
aline and albumin(45,46) in critically ill patients with 
decompensated cirrhosis. Both of these combinations 
result in plasma expansion and systemic vasoconstric-
tion, leading to an increase in effective blood volume and 
a partial or more limited improvement of renal function, 
which may serve as a bridge to LT. However, the efficacy 
of midodrine and octreotide with albumin in achieving 
complete reversal of HRS is low.(12) Midodrine and oct-
reotide is, thus, rarely used in Europe for HRS, and it is 
not recommended in the European Association for the 
Study of the Liver guidelines.(47)
Several randomized controlled trials have evaluated 
the therapeutic effect of terlipressin with albumin and 
found that it is more effective in improving renal func-
tion in patients with HRS compared with other drugs 
or placebo.(11-15,48) Current data show that a terlipressin 
and albumin combination is superior to noradrenaline 
and albumin in patients with ACLF and HRS-AKI.(49) 
In a recent systematic review and meta-analysis, 18 
randomized controlled trials including 1011 patients 
were analyzed. The HRS reversal rate was 42.0% in 
the terlipressin group and 26.2% in the nonterlipres-
sin group. Terlipressin and albumin had a greater HRS 
reversal rate and renal function improvement rate than 
placebo or midodrine/octreotide in the management of 
HRS.(16)
More recently, the results of the CONFIRM trial, 
presented at the AASLD meeting in Boston in 2019, 
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showed a significant reversal in HRS in the terlipres-
sin and albumin arm compared with placebo (29.1% 
versus 15.8%; P  =  0.012).(17) The baseline charac-
teristics of the enrolled patients were similar in both 
groups including the mean MELD scores (32.7 ver-
sus 33; P  =  not significant) and Sequential Organ 
Failure Assessment scores (10.4 versus 10.8; P = not 
significant). The durability of HRS reversal, defined 
as no RRT up to day 30, was significantly higher in 
the terlipressin and albumin arm compared with the 
placebo arm (31.7% versus 15.8%; P  =  0.003).(17) 
Furthermore, the proportion of HRS patients need-
ing RRT after LT was significantly lower in the ter-
lipressin and albumin arm compared with placebo 
(19.6% versus 44.8%; P = 0.04).(17) Similar findings 
were reported from a European study where terlip-
ressin-treated patients had a lower incidence of pre-
transplant and posttransplant RRT and a lower rate 
of chronic kidney disease (CKD) at 1 year.(32)
Terlipressin is a splanchnic vasoconstrictor, there-
fore, monitoring for ischemic events, such as gut 
ischemia, coronary ischemia, and digit ischemia, 
is required, which is similar to noradrenaline. In 
the CONFIRM trial, 9 out of 200 (4.5%) patients 
had ischemic adverse effects.(17) Patient selec-
tion for this therapy is the key given the potential 
for ischemia-related adverse effects with terlipres-
sin.(11-13,15,17,33,46,48) Patients on the transplant wait 
list are highly selected and screened for coronary 
artery disease and are usually low risk for coronary 
artery disease. Terlipressin as a continuous intrave-
nous infusion appears to be as effective as a bolus 
injection with less adverse events.(50)
Reversibility of HRS: Role 
of LT
It is clear from multiple studies that HRS is a largely 
functional prerenal disorder and is potentially re-
versible. This comes from the experience in trans-
plantation medicine, whereby kidneys from patients 
with cirrhosis and HRS exhibited excellent allograft 
function following transplantation into patients with 
end-stage renal disease.(36) Conversely, LT in pa-
tients with HRS frequently leads to normalization 
of kidney function after LT alone.(37,38,51,52) One 
study (n = 2112) reported the cumulative incidence 
of renal nonrecovery, which is defined as a transition 
to chronic dialysis within 6 months of LT, as 8.9% 
among those who were on acute RRT (<90 days) be-
fore LT.(38) The predictors of renal nonrecovery were 
longer duration of pre-LT RRT, diabetes, re-LT, and 
older age.(37,38,52)
Many observational studies have shown that 
patients with HRS-AKI usually have a very high 
MELD score with a high risk of death on the wait 
list.(37,38,52) Additionally, their early posttransplant 
mortality is approximately 20%.(38) None of the 
randomized controlled trials examining the effi-
cacy of terlipressin and albumin specifically enrolled 
LT candidates.(12,13,15) Furthermore, the available 
data from the randomized trials do not address the 
transplant rates, posttransplant renal outcomes, and 
survival among those treated with terlipressin and 
albumin for HRS prior to transplant. The window 
of opportunity for these patients to undergo LT is 
very narrow because of high wait-list mortality, and 
timely transplant is not always available. Therefore, 
it is important to have treatment strategies that may 
serve as a bridge to transplant and could improve 
posttransplant outcomes of wait-listed candidates 
with high MELD scores.
HRS: Role of SLKT
Simultaneous liver-kidney transplantation is an im-
portant option for LT candidates with CKD and 
inherited metabolic diseases, such as primary hyper-
oxaluria, as well as those with sustained AKI deemed 
unlikely to recover after LT alone. It is difficult to 
assess how many patients with sustained AKI will 
have renal recovery after LT alone. Previous studies 
suggest that advanced age, diabetes, re-LT, and pro-
longed duration of RRT before LT are the significant 
predictors of renal nonrecovery after LT alone.(37,52,53) 
The recent SLKT policy, implemented in August 
2017, has medical eligibility criteria and the option 
of a safety net.(54) The safety net is for those LT re-
cipients who do not recover renal function after LT 
alone or who subsequently develop advanced, per-
sistent renal dysfunction within 60-365 days of LT. 
These candidates receive significant priority in the 
kidney allocation system in order to receive an ex-
pedited kidney after LT. SLKT for sustained AKI 
constitutes 6.5% of all SLKT performed in 2018 
(unpublished data from the Scientific Registry of 
Transplant Recipients). Patients with sustained AKI 
who were transplanted and did not recover their renal 
function benefited from the safety net option, which 
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led to a decreased number of SLKTs and an increase 
in kidney transplants after LT in 2018.
HRS Reversibility: Impact 
on MELD Score
Patients with HRS have worse survival for any given 
MELD score when compared with other patients with 
cirrhosis on the LT wait list. Reversal of HRS due to 
a response to terlipressin and albumin will reduce the 
MELD score transiently and can affect a patient’s pri-
ority on the transplant wait list. Therefore, a rescue 
prioritization strategy should be developed for patients 
requiring treatment with terlipressin and albumin be-
cause recurrence of HRS occurs in 20% of responders. 
Updating the MELD scores for patients on the trans-
plant wait list is a dynamic process. For example, those 
with a MELD score >24 need a MELD score update 
every 7 days. Recurrence of HRS occurs in up to 20% 
of responders to terlipressin and albumin,(10) and organ 
availability is not universal for all of the listed candi-
dates. Because the reduction of MELD score can af-
fect the priority on the wait list, a rescue prioritization 
strategy should be developed for patients requiring 
longterm treatment with terlipressin and albumin due 
to the recurrence of HRS.
HRS reversal on terlipressin and albumin may 
reduce MELD score transiently. There should be 
a mechanism so that these patients are not disad-
vantaged by the transient reduction in MELD score 
because of improvement in sCr. To maintain the prior-
ity of treated HRS patients on the wait list, the Liver 
and Intestine Transplant Committee should consider 
either a weighted pretreatment sCr value (similar 
to when RRT is used) or an exception MELD score 
mechanism until we get the real-world experience in 
the United States following terlipressin’s anticipated 
approval by the US Food and Drug Administration. 
This is very important to ensure the optimal pretrans-
plant management of HRS in the listed candidates 
without the concerns as to whether such treatments 
might decrease their prioritization for LT.
Furthermore, poor renal function and the use of 
RRT increases wait-list and posttransplant mortal-
ity.(19,20,53,55,56) Unlike splanchnic vasoconstrictor 
therapy, RRT does not reverse the underlying pro-
cess leading to HRS. Furthermore, the downstream 
adverse effects of RRT, such as venous access bleeding, 
infections, electrolyte abnormality, fluid overload, and 
cardiac events, may further increase morbidity, read-
missions, and mortality in a wait-listed patient.
Renal failure requiring hemodialysis after trans-
plantation is a major risk factor for death in LT 
recipients. Patients who require posttransplant dial-
ysis also have significantly worse graft survival com-
pared with those without posttransplant RRT.(53,55) 
In a single-center study, 75.8% of patients with pre-
transplant patients had resolution of HRS after LT. 
Like other studies, those who had higher pretrans-
plant sCr, longer duration of AKI, and RRT before 
LT were less likely to have renal recovery following 
LT.(37,38) These patients may need a kidney trans-
plant later. Moreover, improving renal function in 
patients with HRS following treatment with terlip-
ressin and albumin should reduce the cost of post-LT 
AKI-related morbidity and resource utilization as 
well as the need for SLKT, and it should result in 
better posttransplant outcomes.
Conclusions
HRS is an ominous complication of portal hyperten-
sion associated with very high morbidity and mortality. 
We hope that with the success of the CONFIRM trial 
in achieving HRS type 1 reversal,(17) terlipressin may 
get approved for its use in the management of HRS. 
This will be an important therapeutic advancement for 
the patients with decompensated cirrhosis and HRS 
in the United States. It will most certainly be incorpo-
rated in the treatment algorithm for the management 
of HRS similar to European and Asian HRS manage-
ment guidelines. The availability of terlipressin and 
albumin for HRS may serve as a bridge to transplant 
in wait-listed LT candidates and may improve their 
pretransplant and posttransplant outcomes including 
renal outcomes.
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